All data are based on the daily closing price as of November 13, 2026
h

Handa Pharmaceuticals

6620.TWO
3.62 USD
-0.11
-2.95%

Overview

Last close
3.62 usd
Market cap
510.94M usd
52 week high
4.91 usd
52 week low
2.10 usd
Target price
2.52 usd

Valuation

P/E
40.2027
Forward P/E
N/A
Price/Sales
15.8178
Price/Book Value
3.9418
Enterprise Value
489.98M usd
EV/Revenue
13.3034
EV/EBITDA
20.613

Key financials

Revenue TTM
36.83M usd
Gross Profit TTM
29.98M usd
EBITDA TTM
18.40M usd
Earnings per Share
0.09 usd
Dividend
0.06 usd
Total assets
175.54M usd
Net debt
N/A usd

About

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; Varenicline tablet and HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
  • Symbol
    6620.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Guo-Chun Song Ph.D.
  • Headquarter
    Tainan City
  • Web site
    https://www.handapharma.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top